Understand the source comparison
Summary: ACE-031 vs Follistatin for Muscle Research
ACE-031 and Follistatin both effectively block the myostatin/activin superfamily Smad2/3 pathway in skeletal muscle, producing quantitatively similar outcomes in myostatin-only challenge models (myotube diameter, MHC expression, pAkt/mTOR restoration). The mec
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ACE-031 and Follistatin both effectively block the myostatin/activin superfamily Smad2/3 pathway in skeletal muscle, producing quantitatively similar outcomes in myostatin-only challenge models (myotube diameter, MHC expression, pAkt/mTOR restoration). The mechanistic hierarchy emerges in activin A–dominant research contexts: Follistatin’s 10–100× higher activin A affinity (Kd 50–200 pM vs ACE-031 ~0.5–1 nM) provides superior muscle research applications in cachexia models (62–72% vs 52–64% mass research applications), superior satellite cell activation in aged and regenerating muscle (+34–42% vs +28–34% Pax7+ density), and superior myotube diameter research applications under dual activin A + myostatin challenge. ACE-031’s advantages are pharmacokinetic (long Fc-mediated circulating half-life ~14 days enabling twice-weekly systemic dosing), convenience for systemic research without osmotic pump, and broader GDF-11 capture (relevant if GDF-11 biology is a research co-variable). ACE-031
- William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.